---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018793"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:24:15.786346+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara posts Q1 net loss of $74.8M; R&D head and CTO to depart in May/June

## Summary
- Net loss of $74.8M ($0.72/sh) vs $88.1M ($0.87/sh) in Q1 2022; cash $205.4M, runway into Q2 2024.
- Jakob Dupont (EVP Global R&D) resigns effective May 12, 2023; Charlene Banard (CTO) departs June 9, 2023.
- Tab-cel BLA discussions with FDA continue; label expansion data expected Q4 2023.
- ATA188 Phase 2 EMBOLD primary data readout on track for October 2023.
- ATA3219 IND filing for B-cell malignancies anticipated end of Q2 2023.

## SEC filing metadata
- accession: 0000950170-23-018793
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/atra-20230505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018793
- JSON: https://secwatch.observer/filing/0000950170-23-018793.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018793.txt

## Key facts
- Earnings Releases
  Atara Biotherapeutics, Inc. reported the first quarter 2023 results: net income net losses of $74.8 million, EPS $0.72 per share.
  - Period: the first quarter 2023
  - Net income: net losses of $74.8 million
  - EPS: $0.72 per share
  - Result: reported results
  source text: Atara reported net losses of $74.8 million, or $0.72 per share for the first quarter 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm
- Executive change
  Charlene Banard departed as Executive Vice President, Chief Technical Officer at Atara Biotherapeutics, Inc..
  - Action: depart
  - Role: Executive Vice President, Chief Technical Officer
  source text: Charlene Banard, the Company’s Executive Vice President, Chief Technical Officer, will depart the Company effective as of June 9, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm
- Executive change
  Jakob Dupont resigned as Executive Vice President, Global Head of Research and Development at Atara Biotherapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President, Global Head of Research and Development
  source text: Jakob Dupont, M.D., the Company’s Executive Vice President, Global Head of Research and Development, on May 5, 2023, notified the Company of his intention to resign from the Company effective as of May 12, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023018793/0000950170-23-018793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.